Management of Dry Eye Toxicity After Treatment With 177Lu-PSMA-617 Radioligand Therapy

被引：0
|
作者：
Pepin, Abigail [1 ]
Lee, Vivian [2 ]
O'Brien, Sophia [3 ]
Mulugeta, Philipose [3 ]
Taunk, Neil K. [1 ]
机构：
[1] Hosp Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA
[2] Hosp Univ Penn, Dept Ophthalmol, Philadelphia, PA USA
[3] Hosp Univ Penn, Div Nucl Med, Philadelphia, PA USA
来源：
PRACTICAL RADIATION ONCOLOGY | 2024年 / 14卷 / 04期
关键词：
SALIVARY; GLANDS;
D O I：
10.1016/j.prro.2024.04.001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Treatment options for patients with metastatic castration-resistant prostate cancer include use of radioligand therapy with 177LuPSMA-617. 177Lu-PSMA-617 is used to target prostate cancer cells selectively by targeting prostate specific membrane antigen (PSMA); however, PSMA is also expressed on lacrimal glands among other tissues. Herein, we report on a case of a Common Terminology Criteria for Adverse Events version 5 grade 3 dry eye event with concomitant blepharitis after administration of 177Lu-PSMA-617. The patient was managed with neomycin-polymyxin-dexamethasone 3.5-10000-0.1 ophthalmic suspension, artificial tears, lubricating ointments, lid scrubs, and oral antihistamines. (c) 2024 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.
引用
下载
收藏
页码：301 / 304
页数：4
相关论文
共 50 条
  • [41] Relevant tumor sink effect in prostate cancer patients receiving 177Lu-PSMA-617 radioligand therapy
    Filss, Christian
    Heinzel, Alexander
    Mueller, Berthold
    Vogg, Andreas T. J.
    Langen, Karl-Josef
    Mottaghy, Felix M.
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2018, 57 (01): : 19 - 25
  • [42] Dose Escalation Experience with 177Lu-PSMA-617
    Rathke, H.
    Giesel, F. L.
    Flechsig, P.
    Kopka, K.
    Mier, W.
    Hohenfellner, M.
    Haberkorn, U.
    Kratochwil, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S280 - S281
  • [43] 177Lu-PSMA-617 vs Cabazitaxel in MCRPC
    不详
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (04) : 13N - 13N
  • [44] Predictors of better response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
    Ferdinandus, Justin
    Eppard, Elisabeth
    Kuerpig, Stefan
    Gaertner, Florian
    Fimmers, Rolf
    Hauser, Stefan
    Essler, Markus
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [45] Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride
    Ahmadzadehfar, Hojjat
    Zimbelmann, Stefanie
    Yordanova, Anna
    Fimmers, Rolf
    Kuerpig, Stefan
    Eppard, Elisabeth
    Gaertner, Florian C.
    Wei, Xiao
    Hauser, Stefan
    Essler, Markus
    ONCOTARGET, 2017, 8 (33) : 55567 - 55574
  • [46] Radioligand therapy with 177Lu-PSMA-617 of metastatic prostate cancer has already been arrived in clinical use
    Ahmadzadehfar, Hojjat
    Essler, Markus
    Schaefers, Michael
    Rahbar, Kambiz
    NUCLEAR MEDICINE AND BIOLOGY, 2016, 43 (12) : 835 - 835
  • [47] Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Bal, Chandrashekhar
    Sahoo, Ranjit Kumar
    Damle, Nishikant Avinash
    Tripathi, Madhavi
    Seth, Amlesh
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (01) : 19 - 31
  • [48] Predictors of better response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
    Ferdinandus, J.
    Eppard, E.
    Kuerpig, S.
    Gaertner, F.
    Fimmers, R.
    Yordanova, A.
    Hauser, S.
    Essler, M.
    Feldmann, G.
    Ahmadzadehfar, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S212 - S213
  • [49] Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer
    Rahbar, Kambiz
    Bode, Axel
    Weckesser, Matthias
    Avramovic, Nemanja
    Claesener, Michael
    Stegger, Lars
    Boegemann, Martin
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (07) : 522 - 528
  • [50] Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Groener, Daniel
    Cam Tu Nguyen
    Baumgarten, Justus
    Bockisch, Benjamin
    Davis, Karen
    Happel, Christian
    Mader, Nicolai
    Ngoc, Christina Nguyen
    Wichert, Jennifer
    Banek, Severine
    Mandel, Philipp
    Chun, Felix K. H.
    Tselis, Nikolaos
    Gruenwald, Frank
    Sabet, Amir
    EJNMMI RESEARCH, 2021, 11 (01)
12345